-
Zhejiang reference preparation (original research drug) hanging network procurement information combing results are announced
Time of Update: 2022-09-30
, Ltd. bid for, namely Beijing, Hebei, Henan, Hubei, Hunan, Jiangsu, Shandong, Sichuan, Tianjin and Yunnan, with a minimum difference ratio unit price of 260 yuan.
, Ltd. bid for, namely Beijing, Hebei, Henan, Hubei, Hunan, Jiangsu, Shandong, Sichuan, Tianjin and Yunnan, with a minimum difference ratio unit price of 260 yuan.
-
Two Chinese companies were selected as the top 100 global medical devices in 2022
Time of Update: 2022-09-30
In recent years, in the face of new opportunities ushered in by the domestic medical device industry, Mindray Medical has dared to make breakthroughs and continued to increase investment in research and development.
-
National Medical Insurance Bureau: 280 co-ordinated areas have launched direct settlement of 5 types of outpatient chronic disease costs across provinces
Time of Update: 2022-09-30
pharmacieshypertensionmalignant tumor In addition, in order to facilitate the insured to directly settle the treatment costs related to 5 kinds of outpatient chronic diseases in different places across provinces, the National Medical Insurance Service Platform App has added query functions such as inter-provincial outpatient chronic disease notifications.
-
Expanding demand The upstream field of oral medicine has entered a rapid development channel
Time of Update: 2022-09-30
The three core investment areas are developing rapidly R&D capabilities still need to be enhanced Looking at the financing situation of the oral medical industry from January to August this year, invisible orthodontics, dental implants, and oral 3D printing are the three core areas of rising financing fever, and the investment logic and development trends of these three segments have their own characteristics.
-
Under the local pharmaceutical company License-in model, another new drug was approved clinically
Time of Update: 2022-09-30
EVER001 capsules (aka: XNW1011) is a new generation of covalent, reversible BTK inhibitors, Genting Xinyao earlier reached a total of more than 560 million US dollars with Sinovid, China Antibody to develop, manufacture and commercialize XNW1011 for the treatment of kidney disease worldwide.
-
New progress in the collection of proprietary Chinese medicines! The reporting phase has been entered
Time of Update: 2022-09-30
In addition, the Shanxi Provincial Medical Insurance Bureau has also issued a notice to clearly start filling in the relevant procurement data and information of the scope of procurement varieties of the National Proprietary Chinese Medicine Alliance.
-
How can pharmaceutical companies achieve efficient and compliant pharmaceutical production? Follow Schneider Electric to experience the charm of digitalization
Time of Update: 2022-09-30
【Pharmaceutical Network Conference Forum】Traditional pharmaceutical enterprises often have defects such as low production efficiency and low production management level, and the rapid development of t
-
Another pharmaceutical company disclosed the first three quarters of this year's performance pre-increase announcement!
Time of Update: 2022-09-30
On September 26, Besmei released the first three quarters of 2022 performance forecast, it is expected that the net profit attributable to the shareholders of listed companies in the first three quarters of this year (referred to as net profit) will be about 106 million yuan - 119 million yuan, an increase of 141.
-
Spine consumables collection and bidding! Vico becomes the biggest winner?
Time of Update: 2022-09-30
The second national examination in the field of orthopedics meets the needs of 95% of surgeries During the day today, before the winning bid results were officially announced, affected by this news, the orthopedic spine stocks in the A-share market have risen sharply, as of today's close, Weigao Orthopedics rose by 13.
-
The transformation and upgrading of the pharmaceutical industry is accelerating, and the personnel changes of pharmaceutical companies are becoming more and more frequent
Time of Update: 2022-09-30
It is worth noting that from the current point of view, this wave of executive changes is still continuing, and recently a number of multinational pharmaceutical giants have announced new executive appointments.
-
ADC drugs into a new blue ocean, domestic pharmaceutical companies are accelerating the layout!
Time of Update: 2022-09-30
It is worth noting that since First Third Gong Pharmaceutical licensed its two blockbuster products, DS-8201 and DS-1062, to AstraZeneca for more than $6 billion in 2019, the enthusiasm for the research and development of ADC drugs at home and abroad has reached a new height.
-
This province's medical insurance plans to add 7 new diseases! There are rare diseases that can be reimbursed more than 200,000 yuan per year
Time of Update: 2022-09-30
【Pharmaceutical Network Industry News】In order to better protect the outpatient needs of insured persons with chronic diseases, the Anhui Provincial Medical Insurance Bureau recently issued a notice o
-
CDMO industry development space is huge, head enterprises to accelerate the layout into a trend!
Time of Update: 2022-09-30
【Pharmaceutical Network Industry News】Recently, Kailaiying released the news that on September 26, it signed the "Investment Agreement on Investing in the Construction of "Biomedical R&D and Production Integrated Base Project" with the Administrative Committee of Taixing Economic Development Zone of Jiangsu Province (hereinafter referred to as "Taixing Management Committee"), and intends to invest 4-5 billion yuan to build a biomedical R&D and production integration base project in Taixing.
-
The performance of the Chinese medicine sector is clearly differentiated, and the net profit of more than 10 Chinese medicine companies in the first half of the year increased by more than 10%
Time of Update: 2022-09-30
On August 24, Panlong Pharmaceutical released its 2022 interim report, which showed that it achieved revenue of 431 million yuan in the first half of the year, an increase of 7.
-
Domestic AI+ pharmaceutical ushered in a major breakthrough, which will inject a dose of cardiotonic agent into the industry
Time of Update: 2022-09-30
According to "Global AI Pharmaceuticals Entering a New Stage" published by Universal Magazine, from the initial computer-aided drug design (CADD) to today's artificial intelligence drug development (AIDD), AI is currently involved in almost the entire process from drug target discovery to clinical trials.
-
6 pharmaceutical companies disclosed three quarterly report forecasts, all of which were expected to be happy!
Time of Update: 2022-09-30
14% year-on-year On September 19, Kaipu Biologics, a domestic nucleic acid molecular diagnostic products and service provider, released the first three quarters of 2022 performance forecast, during the reporting period, the net profit attributable to the shareholders of listed companies is expected to make a profit of 1.
-
To enable efficient and compliant pharmaceutical manufacturing, the digital tide is on the rise in the industry
Time of Update: 2022-09-30
At the same time, the industry expects that more and more pharmaceutical machinery companies will also use artificial intelligence, big data, digitalization and other technologies and platforms to help pharmaceutical companies accelerate drug research and development and production, and continuously contribute to the high-quality development of the pharmaceutical industry.
-
The third batch of national organizations high-value medical consumables collection and selection results: the average price reduction of 84%
Time of Update: 2022-09-30
The successful bid opening of the collection and procurement of spinal orthopedic consumables will further release the institutional dividends of the reform of collection and reduce the burden on the masses.
-
ADC drugs into a new blue ocean, domestic pharmaceutical companies are accelerating the layout!
Time of Update: 2022-09-30
It is worth noting that since First Third Gong Pharmaceutical licensed its two blockbuster products, DS-8201 and DS-1062, to AstraZeneca for more than $6 billion in 2019, the enthusiasm for the research and development of ADC drugs at home and abroad has reached a new height.
-
CDMO head companies have struck! Big acquisitions, building bases, building platforms...
Time of Update: 2022-09-30
CDMO is one of the segments of CXO and a hot and booming track in recent years, with its business mainly helping innovative drug companies produce and manufacture new drugs. In recent years, with the
